Yesterday, I spent the day at my longevity clinic in Manhattan.
As I mentioned in yesterday’s Market Insights, I continue to believe one of the biggest investment opportunities of the next decade is preventive medicine.
The experience only reinforced that view.
What struck me was not just the amount of testing available today. It was how quickly technologies that once seemed futuristic are becoming accessible.
Full-body MRIs. Advanced cardiac imaging. Multi-cancer early detection tests. Continuous health monitoring. AI-powered diagnostics. Genetic screening.
Many of these tools were either unavailable or prohibitively expensive just a few years ago.
Here I am with an image of my heart that was analyzed by AI to look for any possible blockages or trouble spots.
Now they are steadily moving toward the mainstream.
The Shift From Treating Disease to Preventing It
That matters because our healthcare system has historically been built around treating disease after it appears. The next generation of healthcare will focus on finding disease earlier—or preventing it entirely.
And that shift could create enormous opportunities for investors.
The market has spent the last few years obsessing over artificial intelligence, semiconductors, and data centers. Those trends remain powerful.
But AI may ultimately have one of its greatest impacts inside healthcare.
Imagine a future where an annual checkup includes a blood test capable of identifying dozens of cancers before symptoms appear. A future where AI scans medical images with greater accuracy than human specialists. A future where personalized treatments are designed based on your unique genetic profile.
That future is no longer science fiction.
It is already beginning.
Biotech May Be the Most Overlooked Opportunity
The challenge for investors is that biotechnology stocks have been one of the most neglected sectors in the market.
While technology stocks have soared, many biotech companies remain far below their highs from several years ago.
Capital has largely ignored the sector, creating what I believe may be one of the more attractive risk-reward opportunities available today.
Historically, some of the biggest investment winners emerge when breakthrough innovation collides with depressed valuations.
That setup may be developing in biotech right now.
The Tailwinds Are Building
The global population continues to age. Chronic disease rates continue to rise. Healthcare spending keeps climbing. Governments and insurers increasingly recognize that preventing disease is far less expensive than treating advanced illness.
At the same time, advances in computing power, AI, genetic sequencing, and drug discovery are accelerating the pace of innovation.
In many ways, biotech today reminds me of where artificial intelligence was several years ago.
The technology was advancing rapidly, but most investors had not yet recognized the scale of the opportunity.
Where I See the Biggest Opportunities
Of course, biotech investing can be volatile. Clinical trials fail. Drug approvals get delayed. Individual stocks can experience dramatic swings.
That is why I often prefer focusing on themes rather than chasing a single headline.
Areas such as early cancer detection, AI-driven drug discovery, precision medicine, gene editing, and longevity research could all become major growth industries over the next decade.
And if even a handful of these technologies achieve widespread adoption, the companies leading those innovations could create tremendous shareholder value.
A few biotech and healthcare innovation names worth watching include:
Guardant Health (GH) — A leader in blood-based cancer screening and precision oncology.
Exact Sciences (EXAS) — Best known for Cologuard, with continued expansion into early cancer detection.
Tempus AI (TEM) — Combining artificial intelligence with clinical and genomic data to improve patient outcomes.
CRISPR Therapeutics (CRSP) — One of the pioneers in gene-editing technology with long-term transformative potential.
Viking Therapeutics (VKTX) — A promising player in obesity and metabolic disease treatments, an area likely to see significant growth in the years ahead.
Bottom Line
The healthcare industry has traditionally rewarded treatment. The next phase may reward prevention.
Yesterday's visit reminded me that this shift is already underway. Most people are still focused on the healthcare system of the past.
Investors should start paying attention to the healthcare system of the future — because the companies helping people live longer, healthier lives may become some of the biggest winners of the next bull market.
To your health and wealth,
Matt McCall
Founder, NXT Wave Research
